Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Higher-dose ocrelizumab versus standard-dose ocrelizumab in adults with relapsing multiple sclerosis
MOH_2021-01-06_009614Phase 3Not yet recruiting
- Sponsor
- Roche
- Start
- Dec 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ocrelizumab in multiple sclerosis (MS) (2 arms), sponsored by Roche. Planned start Dec 2020; status: not yet recruiting.
02
Drugs
ocrelizumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on MOH_2021-01-06_009614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-01-06_009614.